Emergent BioSolutions Inc. (EBS)

133.42
NYSE
Prev Close 134.94
Day Low/High 131.60 / 136.02
52 Wk Low/High 39.11 / 137.61
Exchange NYSE
Shares Outstanding 52.92B
Market Cap 7.14B
P/E Ratio 41.65
Div & Yield N.A. (N.A)

Latest News

Emergent BioSolutions Could Correct Lower

Emergent BioSolutions Could Correct Lower

Let's check the charts and come up with a trading strategy.

How to Play Emergent Biosolutions' Continuing Rally

How to Play Emergent Biosolutions' Continuing Rally

Let's check out the latest charts and indicators.

Vaccine Maker Emergent BioSolutions Could Surge Higher in the Months Ahead

Vaccine Maker Emergent BioSolutions Could Surge Higher in the Months Ahead

EBS has been in an uptrend for a long time.

Emergent BioSolutions Appears on a Healthy Trajectory

Emergent BioSolutions Appears on a Healthy Trajectory

Investors may consider dosing up on the long side of this vaccine provider.

Emergent BioSolutions Looks Like It Will Get a Shot in the Arm

Emergent BioSolutions Looks Like It Will Get a Shot in the Arm

EBS stock is poised to make a tradable rally in the weeks ahead.

Military Might: Top Defense & Security ETF and Stock Picks for a Dangerous World

Military Might: Top Defense & Security ETF and Stock Picks for a Dangerous World

Seven experts select their best ideas among aerospace and naval contractors, drones, building security, biological threats and cybersecurity.

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

10 Favorite Healthcare Stocks for 2018: Medical Marijuana to Opioid Treatment

We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.

Six Off the Beaten Path Healthcare Stock Gems

Six Off the Beaten Path Healthcare Stock Gems

These lesser-known diagnostic and life sciences firms are involved in areas from genetic tools to telemedicine.

Tip for 2016: Stay Focused on Your Long-Term Vision

Try and remember that life isn't about Jan. 1 through Dec. 31, so why should your returns be?

Stocks Under $10: Stealth Drug Play

Stocks Under $10: Stealth Drug Play

Portfolio manager David Peltier finds a pharmaceutical name that is quietly growing faster than its peers.

Earnings Continue to Disappoint

Let's see how the manufacturing data stack up over the next 24 hours. On the corporate profit front, earnings continue to be disappointing. Over there, in Europe, UBS (UBS), BP (BP) and Anheuser-Busch InBev (BUD) missed, and their share prices are d...